Adverse events · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Quality of life · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vertebral fracture · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐vertebral fractures · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability: total withdrawals · premenopausal women (age 18–32.7 years)
Vitamin D showed no clear difference in withdrawals from the study for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total hip BMD · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lumbar spine bone mineral density (BMD) · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with ACE inhibitor (low certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs may leads to lower stroke compared with ACE inhibitor (low certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ACE inhibitor (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs probably leads to lower myocardial infarction compared with ARB (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with ARB (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ARB (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with diuretic (moderate certainty).
1 finding from 1 review